Qu Lin

Qu Lin

Auto-generated profile, based on publicly available information

Qu Lin

Department of Medical Oncology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2017 in Oncotarget
Verified
Journal Article
Open access
XCXiu-Rong Cai
Xiu-Rong Cai
XLXing Li
Xing Li
JLJin-Xiang Lin
Jin-Xiang Lin
TWTian-Tian Wang
Tian-Tian Wang
MDMin Dong
Min Dong
XWXiang-Yuan Wu
Xiang-Yuan Wu
Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review

9 October 2020 in Clinical and Experimental Medicine
Verified
Journal Article
Closed access
PDF file
ZLZhi-Huan Lin
Zhi-Huan Lin
JJJun-Rong Jiang
Jun-Rong Jiang
XMXiao-Kun Ma
Xiao-Kun Ma
JCJie Chen
Jie Chen
HLHe-Ping Li
He-Ping Li
QLQu Lin
Qu Lin

1 April 2017 in Current Research in Translational Medicine
Verified
Journal Article
Closed access
QLQ. Lin
Q. Lin
ZLZ.-H. Lin
Z.-H. Lin
JCJ. Chen
J. Chen
JLJ.-X. Lin
J.-X. Lin
XLX. Li
X. Li
MHMingsheng Huang
Mingsheng Huang

1 April 2015 in European Journal of Oncology Nursing
Verified
Journal Article
Closed access
JLJin-Xiang Lin
Jin-Xiang Lin
ZFZu-Yan Fan
Zu-Yan Fan
QLQu Lin
Qu Lin
DWDong-Hao Wu
Dong-Hao Wu
XWXiang-Yuan Wu
Xiang-Yuan Wu
XWXiangbo Wan
Xiangbo Wan

16 February 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
LWLi Wei
Li Wei
ZLZexiao Lin
Zexiao Lin
SXSidong Xie
Sidong Xie
DRDanyun Ruan
Danyun Ruan
WJWen Jiang
Wen Jiang
QLQu Lin
Qu Lin
Metastases typically develop before diagnosis and during the treatment of colorectal cancers, while patients with metastatic colorectal cancers (mCRCs) currently have a poor prognosis. In terms of surgical approaches, adjuvant therapies, and targeted therapies, the treatment of mCRCs has had numerous recent advances. As a targeted agent widely used in mCRCs, cetuximab-based treatment is still under dispute due to its side effects and unstable effect. We present two mCRC cases treated with cetuximab-based therapy, of which two patients achieved complete response and without recurrence for over 22 and 84 months, respectively. To better understand the drug usage, we also reviewed the recent achievements and usage precautions of cetuximab in mCRCs. Present and many previous observations support that cetuximab might be a referred drug in the first-line chemotherapy of mCRCs with wild-type RAS and BRAF and proficient mismatch repair.

28 September 2015 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
ZLZhi-Huan Lin
Zhi-Huan Lin
XLXing Li
Xing Li
YHYing-Fen Hong
Ying-Fen Hong
XMXiao-Kun Ma
Xiao-Kun Ma
DWDong-Hao Wu
Dong-Hao Wu
QLQu Lin
Qu Lin